Blood Pressure Lowering in Essential Hypertension with an Oral Renin Inhibitor, Aliskiren

Hypertension

Volumn 42, Issue 6, 2003, Pages 1137-1143

  Stanton, Alice ^a,b   Jensen, Chris ^c   Nussberger, Juerg ^d   OBrien, Eoin ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c Speedel Pharma AG   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Blood pressure; Blood pressure monitoring, ambulatory; Hypertension, essential; Losartan; Receptors, angiotensin; Renin

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; RENIN; RENIN INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RENIN;

EID: 0347479295     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000101688.17370.87     Document Type: Article

References (41)

1. Oparil S, Haber E. The renin-angiotensin system. N Engl J Med. 1974;291:381-401, 446-457.
2. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease, a unifying hypothesis. Hypertension. 2001;37:1047-1052.
3. Yusef S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
4. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Petersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
5. Weber MA, Neutel JM, Essinger I, Glassman HN, Boger RS, Luther RR. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation. 1990;81:1768-1774.
6. Neutel JM, Luther RR, Boger RS, Weber MA. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J. 1991;122:1094-1000.
7. van den Meiracker AH, Admiraal PJ, Derkx FH, Kleinbloesem C, Man in 't Veld AJ, van Brummelen P, Mulder P, Schalekamp MA. Comparison of blood pressure and angiotensin responses to the renin inhibitor RO 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J Hypertens. 1993;11:831-838.
8. Kobrin I, Viskoper RJ, Laszt A, Bock J, Weber C, Charlon V. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens. 1993;6:349-358.
9. Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Exp Op Invest Drugs. 2001;10:417-426.
10. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grutter MG. Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem Biol. 2000;7:493-504.
11. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:e1-e8.
12. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Phillips HP5332, and Nissei DS-175. Blood Press Monit. 1996:1:55-61.
13. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G. British Hypertension Society guidelines for hypertension management. BMJ. 1999;319:630-635.
14. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Protocol. J Hypertens. 1991;9:573-574.
15. Atkins N, Mee F, O'Brien E. A customized international database system for storing and analysing ambulatory blood pressure measurements and related data. Abstract. J Hypertens. 1994;12:S23.
16. Owens P, Atkins N, O'Brien E. Diagnosis of whitecoat hypertension by ambulatory blood pressure monitoring. Hypertension. 1999;34:267-272.
17. Lefevre G, Duval M, Poncin A. Direct micro-radioimmuno-assay of the new renin inhibitor CGP 60536. J Immunoassay. 2000;21:65-84.
18. Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, Kler L, Brown AN, Francis RJ. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987;9:39-44.
19. Fierens FL, Vanderheyden PM, De Backer JP, Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol. 1999;372:199-206.
20. Vanderheyden PM, Fierens FL, Vauquelin G. Angiotensin 11 type I receptor antagonists: why do some of them produce insurmountable inhibition?. Biochem Pharmacol. 2000;60:1557-1563.
21. Fuchs B, Breithaupt-Grogler K, Belz GG, Roll S, Malerczyk C, Herrmann V, Spahn-Langguth H, Mutschler E. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J Pharm Pharmacol. 2000;52:1075-1083.
22. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin I1 antagonists for hypertension: are there differences in efficacy? Am J Hypertens. 2000;13:418-426.
23. Barlucchi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P. Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res. 2001;88:298-304.
24. Re RN. The nature of intracrine peptide hormone action. Hypertension. 1999;34:534-528.
25. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999;100:354-360.
26. Stanton A, Cox J, Atkins N, O'Malley K, O'Brien E. Cumulative sums in quantifying circadian blood pressure patterns. Hypertension. 1992;19:93-101.
27. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens. 1995;8:311-315.
28. Fagard R, Bielen E, Staessen J, Thijs L, Amery A. Response of ambulatory blood pressure to antihypertensive therapy guided by clinic pressure. Am J Hypertens. 1993;6:648-653.
29. Yudkin PL, Stratton IM. How to deal with regression to the mean in intervention studies. Lancet. 1996;347:241-243.
30. Sunman W, Sever PS. Non-angiotensin effects of angiotensin-converting enzyme inhibitors. Clin Sci. 1993;85:661-670.
31. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angioedema. Lancet. 1998;351:1693-1697.
32. Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept. 1993;43:1-20.
33. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
34. Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension. 1995;26:602-609.
35. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin-inhibition: role of angiotensin II in humans. Hypertension. 1994;23:44-51.
36. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.
37. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1998;31:699-705.
38. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
39. Swanson GN, Harding JW. Discovery of a distinct binding site for angio (3-8), a putative AT4 receptor. Regul Pept. 1993;40:409-419.
40. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide Angiotensin IV. J Clin Invest. 1995;96:2515-2520.
41. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension. 2000;35:985-991. (Correction. 2001;37:183.)